Mevidalen
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2015 (NCT02365571)
Timeline
Indications
Mechanism of action
- Dopamine D1 receptorACTIVATOR
DRD1 activator
- Dopamine D1 receptorPOSITIVE ALLOSTERIC MODULATOR
Dopamine D1 receptor positive allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H]1c2cccc(CCC(C)(C)O)c2C[C@H](CO)N1C(=O)Cc1c(Cl)cccc1Cl- Mol. weight
- 450.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3421729 ↗
Also known as
- ly3154207
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06538116 | Phase 2 | Aug 26, 2024 | Eli Lilly |
| NCT04258826 | Phase 1 | Mar 6, 2020 | Eli Lilly |
| NCT03942029 | Phase 1 | Jun 21, 2019 | Eli Lilly |
| NCT03616795 | Phase 1 | Aug 9, 2018 | Eli Lilly |
| NCT03305809 | Phase 2 | Nov 9, 2017 | Eli Lilly |
| NCT02603861 | Phase 1 | Nov 1, 2015 | Eli Lilly |
| NCT02562768 | Phase 1 | Sep 30, 2015 | Eli Lilly |
| NCT02365571 | Phase 1 | Feb 1, 2015 | Eli Lilly |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 8 | 8 | 2 | 2015 |
1 organizations
Page 1 / 1